1.Palta S, Saroa R, Palta A. 2014. Overview of the coagulation system. Indian J Anaesth., 58(5): 515.

2.Pieters M, Wolberg AS. 2019. Fibrinogen and fibrin: An illustrated review. Res Pract Thromb Haemost., 3(2): 161–72.

3.Fish RJ, Neerman-Arbez M. 2012. Fibrinogen gene regulation. Thromb Haemost., 108(09): 419–26.

4.Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA, Zacharowski K. 2011. Novel Aspects of Fibrin(ogen) Fragments during Inflammation. Mol Med., 17(5–6): 568– 73.

5.Khalil R, Al-Humadi N. 2020. Types of acute phase reactants and their importance in vaccination (Review). Biomed Rep [Internet]. 2020 Feb 11 [cited 2020 Dec 6]; Available from: http:// www.spandidos-publications.com/10.3892/ br.2020.1276

6.Davalos D, Akassoglou K. 2012. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol., 34(1): 43–62.

7.Delvaeye M, Conway EM. 2009. Coagulation and innate immune responses: can we view them separately? Blood, 114(12): 2367–74.

8.Luyendyk JP, Schoenecker JG, Flick MJ. 2019. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood, 133(6): 511–20.

9.Thachil J. 2020. The protective rather than prothromboticfibrinogen in COVID-19 and other inflammatory states. J Thromb Haemost, 18(8): 1849–52.

10.Ng LF, Hibberd ML, Ooi E-E, Tang K-F, Neo S-Y, Tan J, et al. 2004. A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. BMC Infect Dis., 4(1): 34.

11.Han M, Yan W, Huang Y, Yao H, Wang Z, Xi D, et al. 2008. The Nucleocapsid Protein of SARS-CoV Induces Transcription of hfgl2 Prothrombinase Gene Dependent on C/EBP Alpha. J Biochem. (Tokyo). 144(1): 51–62.

12.Simpson-Haidaris PJ, Courtney M-A, Wright TW, Goss R, Harmsen A, Gigliotti F. 1998. Induction of Fibrinogen Expression in the Lung Epithelium during Pneumocystis carinii Pneumonia. Mansfield JM, editor. Infect Immun., 66(9): 4431–9.

13.Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. 2013. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease: Table 1. Thorax. 68(7): 670–6.

14.Carty CL, Heagerty P, Heckbert SR, Jarvik GP, Lange LA, Cushman M, et al. 2010. Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the Cardiovascular Health Study. Ann Hum Genet., 74(1): 1–10.

15.Nugroho J, Wardhana A, Mulia EP, Maghfirah I, Rachmi D. 2020. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis. Clin Hemorheol Microcirc., 13: 1–11.

16.Connors JM, Levy JH. 2020. COVID-19 and its implications for thrombosis and anticoagulation. Blood, 135(23): 2033–40.

17.Han H, Yang L, Liu R, Liu F, Wu K, Li J, et al. 2020. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med CCLM. 58(7): 1116–20.

18.Zou Y, Guo H, Zhang Y, Zhang Z, Liu Y, Wang J, et al. 2020. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. Biosci Trends, 14(4): 285–9.

19.Tang N, Li D, Wang X, Sun Z. 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost., 18(4): 844–7.

20.Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, et al. 2013. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J Thromb Haemost., 11(4): 761–7.

21.Hay?ro?lu M?, Ç?nar T, Tekke?in A?. 2020. Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review. Rev Assoc Médica Bras., 66(6): 842–8.

22.Li Q, Cao Y, Chen L, Wu D, Yu J, Wang H, et al. 2020. Hematological features of persons with COVID-19. Leukemia, 34(8): 2163–72.

23.Aggarwal M, Dass J, Mahapatra M. 2020. Hemostatic Abnormalities in COVID-19: An Update. Indian J Hematol Blood Transfus., 36(4): 616–26.

24.Kara H, Bayir A, Degirmenci S, Kayis SA, Akinci M, Ak A, et al. 2014. D-dimer and D-dimer/fibrinogen ratio in predicting pulmonary embolism in patients evaluated in a hospital emergency department. Acta Clin Belg., 69(4): 240–5.

25.Hajsadeghi S, Kerman SR, Khojandi M, Vaferi H. 2012. Accuracy of D-dimer : fibrinogen ratio to diagnose pulmonary thromboembolism in patients admitted to intensive care units : cardiovascular topic. Cardiovasc J Afr., 23(8): 446–56.

26.Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. 2020. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost., 18(7): 1747–51.

27.Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. 2020. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost., 18(7): 1738–42.

28.Pavoni V, Gianesello L, Pazzi M, Stera C, Meconi T, Frigieri FC. 2020. Evaluation of coagulation function by rotation throm-boelastometry in critically ill patients with severe COVID-19 pneumonia. J. Thromb. Thrombolysis., 50(2): 281–6.

29.Chandel A, Patolia S, Looby M, Dalton H, Bade N, Khangoora V, et al. 2020. Association of D-dimer and fibrinogen magnitude with hypercoagulability by thromboelastographyin severe COVID-19 [Internet]. Intensive Care and Critical Care Medicine; 2020 Jul [cited 2020 Dec 7]. Available from: http://medrxiv.org/lookup/ doi/10.1101/2020.07.27.20162842

30.Wise J. 2020. Covid-19 and thrombosis: what do we know about the risks and treatment? BMJ. May 21; m2058.

31.Maier CL, Barker NA, Sniecinski RM. 2020. Falsely Low Fibrinogen Levels in COVID-19 Patients on Direct Thrombin Inhibitors. Anesth Analg., 131(2): e117–9.

32.Osawa I, Okamoto K, Ikeda M, Otani A, Wakimoto Y, Yamashita M, et al. 2020. Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate. J Thromb Thrombolysis [Internet]. 2020 Sep 12 [cited 2020 Dec 7]; Available from: http://link.springer. com/10.1007/s11239-020-02275-5

33.Aleman MM, Walton BL, Byrnes JR, Wolberg AS. 2014. Fibrinogen and red blood cells in venous thrombosis. Thromb. Res., 133 Suppl 1:S38-40.

34.Klovaite J, Nordestgaard BG, Tybjærg-Hansen A, Benn M. 2013. Elevated fibrinogen levels are associated with risk of pulmonary embolism, but not with deep venous thrombosis. Am J Respir Crit Care Med., 187(3): 286–93.

35.Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost., 18(5): 1023–6.

36.Eljilany I, Elzouki A-N. 2020. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. Vasc Health Risk Manag., 16: 455–62.

37.Abbassi-Ghanavati M, Greer LG, Cunningham FG. 2009. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol., 114: 1326-1331.

38.Hager K, Felicetti M, Seefried G, Platt D. 1994. Fibrinogen and aging. Aging (Milano)., 6(2): 133-8.